[1] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet, 2019; 394, 1467−80. doi:  10.1016/S0140-6736(19)32319-0
[2] Li Y, Wang J, Ma XW, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci, 2016; 12, 1022−31. doi:  10.7150/ijbs.15438
[3] Park EJ, Kang J, Hur H, et al. Different clinical features according to the anastomotic leakage subtypes after rectal cancer surgeries: contained vs. Free leakages. PLoS One, 2018; 13, e0208572. doi:  10.1371/journal.pone.0208572
[4] Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol, 2014; 73, 1079−87. doi:  10.1007/s00280-014-2417-9
[5] Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol, 2014; 32, 513−8.
[6] Lin HQ, Wang L, Zhong XH, et al. Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer. World J Surg Oncol, 2021; 19, 141. doi:  10.1186/s12957-021-02251-0
[7] Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol, 2016; 17, 174−83. doi:  10.1016/S1470-2045(15)00467-2
[8] Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol, 2020; 5, 465−74. doi:  10.1016/S2468-1253(19)30410-8
[9] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature, 2008; 24, 436−44.
[10] Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res, 2016; 4, 83−91. doi:  10.1158/2326-6066.CIR-15-0313
[11] Qayoom H, Sofi S, Mir MA. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. Immunol Res, 2023.
[12] Duan WH, Jin LY, Cai ZC, et al. 2-hexyl-4-pentylenic acid (HPTA) stimulates the radiotherapy-induced abscopal effect on distal tumor through polarization of tumor-associated macrophages. Biomed Environ Sci, 2021; 34, 693−704.
[13] Moses C, Garcia-Bloj B, Harvey AR, et al. Hallmarks of cancer: the CRISPR generation. Eur J Cancer, 2018; 93, 10−8. doi:  10.1016/j.ejca.2018.01.002
[14] Stefaniuk P, Szymczyk A, Podhorecka M. The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies-a narrative review. Cancer Manag Res, 2020; 12, 2961−77. doi:  10.2147/CMAR.S245928
[15] Lai SC, Huang L, Luo SL, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett, 2020; 20, 2763−70. doi:  10.3892/ol.2020.11812
[16] Hua X, Long ZQ, Huang X, et al. The value of prognostic nutritional index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer. Front Oncol, 2020; 9, 1562. doi:  10.3389/fonc.2019.01562
[17] Wang YJ, Chen LJ, Zhang BY, et al. Pretreatment inflammatory-nutritional biomarkers predict responses to neoadjuvant chemoradiotherapy and survival in locally advanced rectal cancer. Front Oncol, 2021; 11, 639909. doi:  10.3389/fonc.2021.639909
[18] Kazi M, Gori J, Sasi S, et al. Prognostic nutritional index prior to rectal cancer resection predicts overall survival. Nutr Cancer, 2022; 74, 3228−35. doi:  10.1080/01635581.2022.2072906
[19] Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. Springer. 2017.
[20] Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 2010; 11, 835−44. doi:  10.1016/S1470-2045(10)70172-8
[21] Chee CG, Kim YH, Lee KH, et al. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a potential imaging biomarker for treatment response and prognosis. PLoS One, 2017; 12, e0182883. doi:  10.1371/journal.pone.0182883
[22] Nie K, Shi LM, Chen Q, et al. Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin Cancer Res, 2016; 22, 5256−64. doi:  10.1158/1078-0432.CCR-15-2997
[23] Horvat N, Veeraraghavan H, Khan M, et al. MR imaging of rectal cancer: radiomics analysis to assess treatment response after neoadjuvant therapy. Radiology, 2018; 287, 833−43. doi:  10.1148/radiol.2018172300
[24] Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994; 73, 2680−6. doi:  10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
[25] Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1997; 12, 19−23. doi:  10.1007/s003840050072
[26] Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008; 113, 57−64. doi:  10.1002/cncr.23516
[27] Trakarnsanga A, Gönen M, Shia J, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst, 2014; 106, dju248.
[28] Feng LL, Liu ZY, Li CF. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digit Health, 2022; 4, e8−17. doi:  10.1016/S2589-7500(21)00215-6
[29] Roxburgh CSD, Salmond JM, Horgan PG, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg, 2009; 13, 2011−9. doi:  10.1007/s11605-009-1034-0
[30] Min KW, Kwon MJ, Kim DH, et al. Persistent elevation of postoperative neutrophil-to-lymphocyte ratio: a better predictor of survival in gastric cancer than elevated preoperative neutrophil-to-lymphocyte ratio. Sci Rep, 2017; 7, 13967. doi:  10.1038/s41598-017-13969-x
[31] Jung SW, Park IJ, Oh SH, et al. Association of immunologic markers from complete blood counts with the response to preoperative chemoradiotherapy and prognosis in locally advanced rectal cancer. Oncotarget, 2017; 8, 59757−65. doi:  10.18632/oncotarget.15760
[32] Dudani S, Marginean H, Tang PA, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer, 2019; 19, 664. doi:  10.1186/s12885-019-5892-x
[33] Caputo D, Caricato M, Coppola A, et al. Neutrophil to lymphocyte ratio (NLR) and derived neutrophil to lymphocyte ratio (d-NLR) predict non-responders and postoperative complications in patients undergoing radical surgery after neo-adjuvant radio-chemotherapy for rectal adenocarcinoma. Cancer Invest, 2016; 34, 440−51. doi:  10.1080/07357907.2016.1229332
[34] Bhudia J, Glynne-Jones R, Smith T, et al. Neoadjuvant chemotherapy without radiation in colorectal cancer. Clin Colon Rectal Surg, 2020; 33, 287−97. doi:  10.1055/s-0040-1713746